FDA approves new bolus vial form of tirofiban hydrochloride

Tim Casey | | Cardiovascular Business | Interventional Cardiology

The FDA approved a bolus vial form of tirofiban hydrochloride (Aggrastat) on Sept. 1.

Medicure, which manufactures and markets tirofiban hydrochloride, said in a news release that the company developed the new product format after hearing from interventional cardiologists and catheterization laboratory nurses.

The new format is a concentrated, pre-mixed, 15 ml vial designed to deliver a 25 mcg/kg bolus dose of tirofiban hydrochloride. The drug will be available in the fourth quarter of this year, according to Medicure.

The FDA has approved tirofiban hydrochloride to reduce the combined endpoint of death, MI or refractory ischemia/repeat cardiac procedures in patients with non-ST elevation acute coronary syndrome.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Related Content

Cardiologists reflect on developing primary PCI in face of criticism and pushback
How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
IVUS-guided PCI reduces risks in patients with diabetes
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
LAAC with Watchman FLX reduces bleeding risks after AFib ablation

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."